Skip to main content

Table 1 Mortality during treatment

From: Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Transplanted cells Treatment Day of treatment (spleen size)
1.5 × 106 Bcr-Abl BM vehicle day 8 (380 mg), day 12 (n.a.)
1.5 × 106 Bcr-Abl BM vehicle + IgG day 9 (274 mg), day 12 (410 mg), day 13 (77 mg)
1.5 × 106 Bcr-Abl BM nilotinib none
1.5 × 106 Bcr-Abl BM nilotinib + infliximab day 7 (91 mg), day 9 (108 mg)
1.5 × 106 wt BM vehicle none